Akari Therapeutics PLC-ADRAKTX
13F holders, Q1 2026 (March 31)6holders
$5.15avg. 13F price*
At the end of Q1 2026, 6 institutions reported holding Akari Therapeutics PLC-ADR (AKTX) in their 13F filings. The largest holders were Armistice Capital, LLC ($200K), Cresset Asset Management, LLC ($106K) and IFP Advisors, Inc ($932).
- Company
- Akari Therapeutics PLC-ADR
- CUSIP
- 00972G405
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $307K |
| Exits | 0 | $0 |
Ownership 6 holders
| Armistice Capital, LLC | 0.01% | New | 38,922 | $200K |
| Cresset Asset Management, LLC | 0.00% | New | 20,561 | $106K |
| IFP Advisors, Inc | 0.00% | New | 181 | $932 |
| SBI Securities Co., Ltd. | 0.00% | New | 5 | $26 |
| Morgan Stanley | 0.00% | New | 1 | $5 |
| Truvestments Capital LLC | 0.00% | New | 1 | $5 |
"% of holder's portfolio" is AKTX's weight in each manager's 13F, not the share of Akari Therapeutics PLC-ADR the manager owns.